Literature DB >> 31657857

CK20 and lymph node involvement predict adverse outcome of malignant intraductal papillary neoplasm of the bile duct.

Jie Shi1, Xueshuai Wan2, Yuan Xie3, Jianzhen Lin2, Junyu Long2, Weiyu Xu2, Zhiyong Liang1, Xinting Sang4, Haitao Zhao5.   

Abstract

OBJECTIVES: To identify prognostic factors of malignant intraductal papillary neoplasm of the bile duct (m-IPNB).
MATERIALS AND METHODS: We included 38 consecutive cases which underwent surgical resection and diagnosed as IPNB with malignant component from January 2003 to January 2017. Clinicopathological variables were collected to conduct survival analysis and identify prognostic factors.
RESULTS: The median overall survival (OS) of m-IPNB was 76.0 months, with 1-, 3-, and 5-year survival rates of 97.2%, 73.5%, and 59.8%, respectively. The median RFS was 48.0 months with 1-, 3-, and 5-year recurrence-free survival (RFS) rate was 83.2%, 59.8%, and 44.6%, respectively. Univariate analysis showed that elevation of carcinoembryonic antigen CEA, lymph node involvement, resection margin status, degree of periductal invasion, and positive expression of CK20 were associated with both OS and RFS of m-IPNB. After multivariate Cox models analysis, lymph node involvement and positive expression of CK20 were identified as independent prognostic factors for OS, while lymph node involvement and resection margin status were independent prognostic factors for RFS. The median OS of patients with m-IPNB involving lymphatic metastases and positive expression of CK20 was 27.0±8.8 months and 51.0±12.4 months, respectively. The median RFS of cases with lymph node involvement and R1 resection was 10.0±3.3 months and 25.0±6.9 months, respectively. However, there was no significant difference in OS or RFS between cases of pancreaticobiliary and intestinal subtype.
CONCLUSIONS: Lymph node involvement and positive expression of CK20 are independent prognostic factors for shorter OS of m-IPNB, while patients with lymph node involvement and positive resection margin are at higher risk of tumor recurrence.

Entities:  

Year:  2019        PMID: 31657857     DOI: 10.14670/HH-18-179

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  31 in total

Review 1.  Mucins in cancer: protection and control of the cell surface.

Authors:  Michael A Hollingsworth; Benjamin J Swanson
Journal:  Nat Rev Cancer       Date:  2004-01       Impact factor: 60.716

2.  Recurrent Mutations in APC and CTNNB1 and Activated Wnt/β-catenin Signaling in Intraductal Papillary Neoplasms of the Bile Duct: A Whole Exome Sequencing Study.

Authors:  Kohei Fujikura; Masayuki Akita; Tetsuo Ajiki; Takumi Fukumoto; Tomoo Itoh; Yoh Zen
Journal:  Am J Surg Pathol       Date:  2018-12       Impact factor: 6.394

3.  Clinicopathologic features of intraductal papillary neoplasm of the bile duct according to histologic subtype.

Authors:  Kwang Min Kim; Jong Kyun Lee; Jae Uk Shin; Kwang Hyuck Lee; Kyu Taek Lee; Ji-Youn Sung; Kee-Taek Jang; Jin Seok Heo; Seong-Ho Choi; Dong Wook Choi; Jae Hoon Lim
Journal:  Am J Gastroenterol       Date:  2011-09-27       Impact factor: 10.864

4.  CDX2 and MUC2 protein expression in extrahepatic bile duct carcinoma.

Authors:  Seung-Mo Hong; HyungJun Cho; Christopher A Moskaluk; Henry F Frierson; Eunsil Yu; Jae Y Ro
Journal:  Am J Clin Pathol       Date:  2005-09       Impact factor: 2.493

5.  Long-term clinical outcome of the surgically resected intraductal papillary neoplasm of the bile duct.

Authors:  Geunyoung Jung; Kwang-Min Park; Seung Soo Lee; Eunsil Yu; Seung-Mo Hong; Jihun Kim
Journal:  J Hepatol       Date:  2012-05-23       Impact factor: 25.083

6.  Impact of macroscopic morphology, multifocality, and mucin secretion on survival outcome of intraductal papillary neoplasm of the bile duct.

Authors:  Mee Joo Kang; Jin-Young Jang; Kyoung Bun Lee; In Woong Han; Sun-Whe Kim
Journal:  J Gastrointest Surg       Date:  2013-01-31       Impact factor: 3.452

7.  Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas.

Authors:  N Volkan Adsay; Kambiz Merati; Olca Basturk; Christine Iacobuzio-Donahue; Edi Levi; Jeanette D Cheng; Fazlul H Sarkar; Ralph H Hruban; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2004-07       Impact factor: 6.394

Review 8.  Systematic Review and Meta-analysis of Current Experience in Treating IPNB: Clinical and Pathological Correlates.

Authors:  Alex N Gordon-Weeks; Keaton Jones; Elinor Harriss; Adrian Smith; Michael Silva
Journal:  Ann Surg       Date:  2016-04       Impact factor: 12.969

9.  Outcomes of surgery for 2010 WHO classification-based intraductal papillary neoplasm of the bile duct: Case-control study of a single Japanese institution's experience with special attention to mucin expression patterns.

Authors:  Fumi Harada; Ryusei Matsuyama; Ryutaro Mori; Takafumi Kumamoto; Daisuke Morioka; Masataka Taguri; Shoji Yamanaka; Itaru Endo
Journal:  Eur J Surg Oncol       Date:  2018-10-24       Impact factor: 4.424

10.  Aberrant expression of CDX2 is closely related to the intestinal metaplasia and MUC2 expression in intraductal papillary neoplasm of the liver in hepatolithiasis.

Authors:  Akira Ishikawa; Motoko Sasaki; Shusaku Ohira; Tetsuo Ohta; Koji Oda; Yuji Nimura; Miin-Fu Chen; Yi-Yin Jan; Ta-Sen Yeh; Yasuni Nakanuma
Journal:  Lab Invest       Date:  2004-05       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.